全文获取类型
| 收费全文 | 16672篇 |
| 免费 | 22篇 |
| 国内免费 | 5篇 |
专业分类
| 耳鼻咽喉 | 20篇 |
| 儿科学 | 194篇 |
| 妇产科学 | 171篇 |
| 基础医学 | 449篇 |
| 口腔科学 | 55篇 |
| 临床医学 | 268篇 |
| 内科学 | 6225篇 |
| 皮肤病学 | 373篇 |
| 神经病学 | 454篇 |
| 特种医学 | 389篇 |
| 外科学 | 5695篇 |
| 综合类 | 30篇 |
| 预防医学 | 285篇 |
| 眼科学 | 1073篇 |
| 药学 | 163篇 |
| 中国医学 | 10篇 |
| 肿瘤学 | 845篇 |
出版年
| 2024年 | 1篇 |
| 2023年 | 8篇 |
| 2022年 | 22篇 |
| 2021年 | 299篇 |
| 2020年 | 8篇 |
| 2019年 | 3286篇 |
| 2018年 | 2499篇 |
| 2017年 | 1296篇 |
| 2016年 | 10篇 |
| 2015年 | 22篇 |
| 2014年 | 57篇 |
| 2013年 | 31篇 |
| 2012年 | 32篇 |
| 2011年 | 31篇 |
| 2010年 | 19篇 |
| 2009年 | 19篇 |
| 2008年 | 20篇 |
| 2007年 | 14篇 |
| 2006年 | 7篇 |
| 2005年 | 10篇 |
| 2004年 | 8篇 |
| 2003年 | 10篇 |
| 2002年 | 4篇 |
| 2001年 | 70篇 |
| 2000年 | 59篇 |
| 1999年 | 64篇 |
| 1998年 | 3篇 |
| 1997年 | 1篇 |
| 1996年 | 1篇 |
| 1994年 | 10篇 |
| 1993年 | 2篇 |
| 1992年 | 1篇 |
| 1991年 | 10篇 |
| 1990年 | 1篇 |
| 1988年 | 23篇 |
| 1985年 | 750篇 |
| 1984年 | 1284篇 |
| 1983年 | 1256篇 |
| 1982年 | 879篇 |
| 1981年 | 734篇 |
| 1980年 | 715篇 |
| 1979年 | 757篇 |
| 1978年 | 622篇 |
| 1977年 | 218篇 |
| 1976年 | 582篇 |
| 1975年 | 495篇 |
| 1974年 | 212篇 |
| 1973年 | 237篇 |
排序方式： 共有10000条查询结果，搜索用时 31 毫秒
91.
P. Mendogni S. Henchi L.C. Morlacchi D. Tosi M. Nosotti P. Tarsia A.I. Gregorini L. Rosso 《Transplantation proceedings》2019,51(1):194-197
Background
Solid organ transplantation is associated with a higher risk of Epstein-Barr virus (EBV)–related lymphoproliferative disease due to immunosuppressive regimen. Little evidence is currently available on post-transplant lymphoproliferative disorders (PTLDs) in the lung transplant (LuTx) setting, particularly in cystic fibrosis (CF) recipients.Methods
We retrospectively analyzed all the cases of PTLDs that occurred in our LuTx center between January 2015 and December 2017. We reviewed clinical and radiologic data, donor and recipient EBV serostatus, immunosuppressive therapy, histologic data, and follow-up of these patients.Results
A total of 77 LuTxs were performed at our center in the study period; 39 (50.6%) patients had CF; 4 developed EBV-related PTLDs. They were all young (17–26 years) CF patients with high serum EBV DNA load. Disease onset was within the first 3 months after LuTx. In 3 cases presentation was associated with fever and infection-like symptoms, whereas in 1 case radiologic suspicion arose unexpectedly from a CT scan performed for different clinical reasons. Diagnosis was reached through lung biopsy in all cases. All patients received rituximab,?cyclophosphamide, doxorubicin hydrochloride (hydroxydaunomycin), vincristine sulfate (Oncovin), and prednisone with variable response and complications.Conclusion
In our experience, the early development of EBV-related PTLD was a highly aggressive, life-threatening condition, which exclusively affected young CF patients in the early post-transplant period. The rate of this complication was relatively high in our population.Diagnosis with lung biopsy is crucial in all suspected cases and regular monitoring of EBV DNA levels is of utmost importance given the high correlation with PTLDs in patients at increased risk. 相似文献92.
93.
94.
95.
96.
97.
98.
99.
100.